These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 20529685)

  • 1. MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.
    Kolodziej SA; Hockerman SL; DeCrescenzo GA; McDonald JJ; Mischke DA; Munie GE; Fletcher TR; Stehle N; Swearingen C; Becker DP
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3561-4. PubMed ID: 20529685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.
    Kolodziej SA; Hockerman SL; Boehm TL; Carroll JN; DeCrescenzo GA; McDonald JJ; Mischke DA; Munie GE; Fletcher TR; Rico JG; Stehle NW; Swearingen C; Becker DP
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3557-60. PubMed ID: 20529684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.
    Fobian YM; Freskos JN; Barta TE; Bedell LJ; Heintz R; Kassab DJ; Kiefer JR; Mischke BV; Molyneaux JM; Mullins P; Munie GE; Becker DP
    Bioorg Med Chem Lett; 2011 May; 21(10):2823-5. PubMed ID: 21493063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MMP-13 selective α-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.
    Barta TE; Becker DP; Bedell LJ; Easton AM; Hockerman SL; Kiefer J; Munie GE; Mathis KJ; Li MH; Rico JG; Villamil CI; Williams JM
    Bioorg Med Chem Lett; 2011 May; 21(10):2820-2. PubMed ID: 21507637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.
    Tommasi RA; Weiler S; McQuire LW; Rogel O; Chambers M; Clark K; Doughty J; Fang J; Ganu V; Grob J; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Melton R; Springer C; Walker M; Zhang J; Zhu L; Shultz M
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6440-5. PubMed ID: 21937229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.
    Becker DP; Barta TE; Bedell LJ; Boehm TL; Bond BR; Carroll J; Carron CP; Decrescenzo GA; Easton AM; Freskos JN; Funckes-Shippy CL; Heron M; Hockerman S; Howard CP; Kiefer JR; Li MH; Mathis KJ; McDonald JJ; Mehta PP; Munie GE; Sunyer T; Swearingen CA; Villamil CI; Welsch D; Williams JM; Yu Y; Yao J
    J Med Chem; 2010 Sep; 53(18):6653-80. PubMed ID: 20726512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
    Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
    J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent, selective pyrimidinetrione-based inhibitors of MMP-13.
    Reiter LA; Freeman-Cook KD; Jones CS; Martinelli GJ; Antipas AS; Berliner MA; Datta K; Downs JT; Eskra JD; Forman MD; Greer EM; Guzman R; Hardink JR; Janat F; Keene NF; Laird ER; Liras JL; Lopresti-Morrow LL; Mitchell PG; Pandit J; Robertson D; Sperger D; Vaughn-Bowser ML; Waller DM; Yocum SA
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5822-6. PubMed ID: 16942871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.
    Noe MC; Natarajan V; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Otterness I; Bliven MA; Carty TJ; Barberia JT; Sweeney FJ; Liras JL; Vaughn M
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3385-8. PubMed ID: 15953722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy.
    Becker DP; Villamil CI; Barta TE; Bedell LJ; Boehm TL; Decrescenzo GA; Freskos JN; Getman DP; Hockerman S; Heintz R; Howard SC; Li MH; McDonald JJ; Carron CP; Funckes-Shippy CL; Mehta PP; Munie GE; Swearingen CA
    J Med Chem; 2005 Oct; 48(21):6713-30. PubMed ID: 16220987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.
    Yang SM; Scannevin RH; Wang B; Burke SL; Wilson LJ; Karnachi P; Rhodes KJ; Lagu B; Murray WV
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1135-9. PubMed ID: 18086526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel series of highly selective inhibitors of MMP-3.
    Whitlock GA; Dack KN; Dickinson RP; Lewis ML
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and activity of quinolinylmethyl P1' alpha-sulfone piperidine hydroxamate inhibitors of TACE.
    Zhang C; Lovering F; Behnke M; Zask A; Sandanayaka V; Sun L; Zhu Y; Xu W; Zhang Y; Levin JI
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3445-8. PubMed ID: 19464885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A peptide hydroxamate library for enrichment of metalloproteinases: towards an affinity-based metalloproteinase profiling protocol.
    Geurink P; Klein T; Leeuwenburgh M; van der Marel G; Kauffman H; Bischoff R; Overkleeft H
    Org Biomol Chem; 2008 Apr; 6(7):1244-50. PubMed ID: 18362965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of an orally active matrix metalloproteinase inhibitor.
    Yamamoto S; Nakatani S; Ikura M; Sugiura T; Nishita Y; Itadani S; Ogawa K; Ohno H; Takahashi K; Nakai H; Toda M
    Bioorg Med Chem; 2006 Sep; 14(18):6383-403. PubMed ID: 16765051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.
    Yang SM; Scannevin RH; Wang B; Burke SL; Huang Z; Karnachi P; Wilson LJ; Rhodes KJ; Lagu B; Murray WV
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1140-5. PubMed ID: 18083558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.
    Becker DP; DeCrescenzo G; Freskos J; Getman DP; Hockerman SL; Li M; Mehta P; Munie GE; Swearingen C
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2723-5. PubMed ID: 11591510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.
    Noe MC; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Liras JL; Vaughn M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4727-30. PubMed ID: 15324896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-O-isopropyl sulfonamido-based hydroxamates: kinetic characterisation of a series of MMP-12/MMP-13 dual target inhibitors.
    Santamaria S; Nuti E; Cercignani G; Marinelli L; La Pietra V; Novellino E; Rossello A
    Biochem Pharmacol; 2012 Sep; 84(6):813-20. PubMed ID: 22771631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. alpha-Amino-beta-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1.
    Becker DP; Barta TE; Bedell L; DeCrescenzo G; Freskos J; Getman DP; Hockerman SL; Li M; Mehta P; Mischke B; Munie GE; Swearingen C; Villamil CI
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2719-22. PubMed ID: 11591509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.